EMJ Respiratory Highlights Tozorakimab's 34% COPD Exacerbation Reduction
The latest edition of EMJ Respiratory discusses how tozorakimab reduced COPD exacerbations by up to 34%. It also explores the broader causes of breathlessness beyond lung issues, providing insights into respiratory health and treatment advancements.
EMJ·


